<DOC>
	<DOCNO>NCT00006110</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Monoclonal antibody trastuzumab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . Combining chemotherapy , monoclonal antibody therapy , surgery may effective treatment breast cancer . PURPOSE : Phase II trial study effectiveness combination chemotherapy , monoclonal antibody therapy , surgery treat woman stage II , stage III , stage IV breast cancer .</brief_summary>
	<brief_title>Multimodality Treatment Women With Stage II , Stage III , Stage IV Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine cardiac toxicity paclitaxel administer trastuzumab ( Herceptin ) doxorubicin cyclophosphamide woman stage IIB , IIIA , IIIB , IIIC , previously untreated stage IV breast cancer . - Determine whether addition paclitaxel without trastuzumab conventional breast cancer adjuvant therapy ( doxorubicin cyclophosphamide ) decrease tumor size number positive axillary node patient . - Determine 5-year disease-free survival overall survival patient treat regimen . - Determine whether initial pathologic response patient receive neoadjuvant therapy correlate eventual 5-year disease-free survival overall survival . - Compare number patient eligible breast-conserving cancer surgery treatment doxorubicin cyclophosphamide v paclitaxel trastuzumab . - Correlate clinical radiographic response rate pathologic response rate primary tumor axillary lymph node determine parameter best determines pathologic response rate patient treat regimen . OUTLINE : Patients assign receive either neoadjuvant therapy ( HER-2 overexpressing nonoverexpressing patient ) adjuvant therapy ( HER-2 overexpressing patient ) . - Neoadjuvant therapy : Patients assign receive neoadjuvant therapy receive one two treatment regimen . - Regimen I ( HER-2 nonoverexpressing patient HER-2 overexpressing patient refuse trastuzumab ( Herceptin ) therapy ) : Patients receive doxorubicin IV cyclophosphamide IV 30 minute paclitaxel IV 3 hour day 1 every 3 week total 4 course . Patients undergo surgery without adjuvant radiotherapy and/or oral tamoxifen . - Regimen II ( HER-2 overexpressing patient ) : Patients receive doxorubicin cyclophosphamide regimen I . After completion course 4 , patient receive paclitaxel IV trastuzumab IV 90-150 minute weekly week 13-24 . Patients undergo surgery without adjuvant radiotherapy . Patients receive trastuzumab IV 30 minute weekly week 29-69 receive radiotherapy week 36-76 receive radiotherapy . - Adjuvant therapy : Patients assign receive adjuvant therapy ( HER-2 overexpressing patient ) receive doxorubicin IV cyclophosphamide IV 30 minute day 1 every 3 week total 4 course . After completion course 4 , patient receive paclitaxel IV trastuzumab IV 90 minute weekly week 13-24 . Patients may undergo radiotherapy follow trastuzumab IV 30 minute weekly week 29-69 receive radiotherapy week 36-76 receive radiotherapy . Patients follow every 3 month 2 year , every 6 month 3 year , annually 5 year . PROJECTED ACCRUAL : A total 125 patient ( 100 neoadjuvant group 25 adjuvant group ) accrue study within 5 year .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage IIB , IIIA , IIIB , IIIC , previously untreated stage IV primary carcinoma breast Fine needle aspiration , core needle biopsy , incisional biopsy allow No excisional biopsy Any following : T2 , N1 T3 , N0 Any T N2 ( include axillary lymph node mat one another ) N3 Any T4 , include inflammatory breast cancer Adjuvant patient least 4 positive lymph node HER2 overexpressing tumor Supraclavicular infraclavicular positive lymph node without distant metastasis Distant metastases measurable disease breast lymph node Synchronous bilateral primary breast cancer allow serious cancer meet entry criterion Measurable evaluable disease Hormone receptor status : Not specify PATIENT CHARACTERISTICS : Age : Not specify Sex : Female Menopausal status : Not specify Performance status : Not specify Life expectancy : Not specify Hematopoietic : WBC great 3,000/mm^3 Platelet count great 100,000/mm^3 Hemoglobin great 9 g/dL Hepatic : Bilirubin le 1.5 time normal Renal : Creatinine le 1.5 time normal Cardiovascular : LVEF normal rest nuclear ventriculogram Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior malignancy except : Effectively treat squamous cell basal cell skin cancer Carcinoma situ cervix curatively treat surgery alone Nonbreast malignancy patient diseasefree 5 year low risk recurrence PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : Not specify Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>inflammatory breast cancer</keyword>
</DOC>